- Conditions
- Multiple Sclerosis
- Interventions
- Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 7,451
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 10
- States / cities
- Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carmustine, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 218
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Eluxadoline, Placebo
- Drug
- Lead sponsor
- Furiex Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 232
- States / cities
- Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more
- Conditions
- Actinic Keratoses
- Interventions
- PEP005 (ingenol mebutate) Gel, Vehicle gel
- Drug
- Lead sponsor
- Peplin
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 18
- States / cities
- Mesa, Arizona • Denver, Colorado • Kissimmee, Florida + 14 more
- Conditions
- Cryptococcal Meningitis
- Interventions
- Amphotericin B, Fluconazole
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 5 more
- Conditions
- Neoplasms, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Interventions
- TPI 287 Injection
- Drug
- Lead sponsor
- Cortice Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Breast Cancer
- Interventions
- Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
- Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 3,960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 1226
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Ixo-vec, Aflibercept
- Genetic · Drug
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 79
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- Renal Autologous Cell Therapy (REACT), Renal Biopsy
- Biological · Procedure
- Lead sponsor
- Prokidney
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Denver, Colorado • New Haven, Connecticut + 13 more
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- Ublituximab
- Biological
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2032
- U.S. locations
- 19
- States / cities
- Pasadena, California • Denver, Colorado • Miami, Florida + 16 more
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
- Interventions
- Capecitabine, Temozolomide
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 446
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 300 more
- Conditions
- COVID-19
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Metastasis
- Interventions
- THOR-707, Checkpoint inhibitor, anti-EGFR antibody
- Drug
- Lead sponsor
- Synthorx, Inc, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more
- Conditions
- Advanced/Metastatic Colorectal Adenocarcinoma
- Interventions
- BAY 3771249, Cetuximab
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Duarte, California • San Diego, California + 4 more
- Conditions
- Sickle Cell Disease
- Interventions
- Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER, High Dose Rifaximin DER, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Orange, California • Denver, Colorado • Atlanta, Georgia + 2 more
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Alzheimers, Frontotemporal Dementia
- Interventions
- Care Ecosystem
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- San Francisco, California • Torrance, California • Denver, Colorado + 3 more
- Conditions
- HIV Infections
- Interventions
- Ritonavir, Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Delavirdine mesylate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1999
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 27 more
- Conditions
- Growth, Body Composition, Gut Health
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 4 Years to 7 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Pleuropulmonary Blastoma
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Dexrazoxane, Doxorubicin, Echocardiography Test, Ifosfamide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Patient Observation, Positron Emission Tomography, Topotecan, Ultrasound Imaging, Vincristine
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 71 more
- Conditions
- Seasonal Influenza
- Interventions
- mRNA-1010, Fluarix Quadrivalent
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 22,502 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 134
- States / cities
- Athens, Alabama • Glendale, Arizona • Phoenix, Arizona + 110 more
- Conditions
- Severe Eosinophilic Asthma, Nasal Polyps
- Interventions
- FASENRA(benralizumab)
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Centennial, Colorado • Denver, Colorado • Glendale, New York + 5 more
- Conditions
- Multiple Sclerosis
- Interventions
- Duloxetine Hydrochloride (HCI), Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
- Conditions
- Atrial Fibrillation
- Interventions
- Intervention, Control
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Denver, Colorado